Pharmaceutical Research

, Volume 30, Issue 4, pp 1026–1036 | Cite as

Erythropoietin-Induced Erythroid Precursor Pool Depletion Causes Erythropoietin Hyporesponsiveness

  • Xiaoyu Yan
  • Sihem Ait-Oudhia
  • Wojciech Krzyzanski
Research Paper

Abstract

Purpose

The purpose of this study is to demonstrate that the erythroid precursor depletion in bone marrow induced by recombinant human erythropoietin (rHuEPO) treatment may be another contributing factor to erythropoietin hyporesponsiveness.

Methods

Healthy Wistar rats were given single dose (SD) or multiple doses (MD) of rHuEPO (100 IU/kg). In MD study, animals were challenged with thrice-weekly over two weeks. Blood, bone marrow and spleen (for SD only) were collected. The erythropoietic responses in bone marrow and spleen were quantified using a flow cytometric immunophenotyping technique. A mathematical approach involving measuring reticulocyte age distribution was developed to evaluate the reticulocyte loss due to neocytolysis.

Results

A reduced level of erythropoietic responses below the baseline was observed for both MD and SD studies. In SD study, the reticulocyte decreased below the baseline after day 6. A depletion of the bone marrow erythroid precursor cells was observed. However, neocytolysis of reticulocyte only occurs from day 3-5 after rHuEPO injection.

Conclusions

The findings demonstrate that EPO-induced erythroid precursor depletion in bone marrow is responsible for reduced reticulocyte response and may contribute to erythropoietin hyporesponsiveness. Therefore, this study provides further justification for reducing the doses of erythropoietin-stimulating agents in anemic patients demonstrating hyporesponsiveness.

KEY WORDS

dynamics erythroid precursor depletion erythropoietin hyporesponsiveness tolerance 

Notes

Acknowledgments and Disclosures

This work was supported by the National Institutes of Health Grant GM 57980

References

  1. 1.
    Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. Curr Opin Hematol. 2002;9(2):93–100.PubMedCrossRefGoogle Scholar
  2. 2.
    Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol. 2008;36(12):1573–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol. 2005;15(3):146–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Koury MJ, Bondurant MC. Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol. 1988;137(1):65–74.PubMedCrossRefGoogle Scholar
  5. 5.
    Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia. 2004;18(7):1176–99.PubMedCrossRefGoogle Scholar
  6. 6.
    Wintrobe MM, Greer JP. Wintrobe’s clinical hematology: Lippincott Williams & Wilkins; 2004.Google Scholar
  7. 7.
    Raff MC. Social controls on cell survival and cell death. Nature. 1992;356(6368):397–400.PubMedCrossRefGoogle Scholar
  8. 8.
    Hillman RS. Characteristics of marrow production and reticulocyte maturation in normal man in response to anemia. J Clin Invest. 1969;48(3):443–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Major A, Bauer C, Breymann C, Huch A, Huch R. rh-erythropoietin stimulates immature reticulocyte release in man. Br J Haematol. 1994;87(3):605–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Rodak BF, Fritsma GA, Doig K. Hematology: clinical principles and applications. 3rd ed. St. Louis: Saunders Elsevier; 2007.Google Scholar
  11. 11.
    Chasis JA, Prenant M, Leung A, Mohandas N. Membrane assembly and remodeling during reticulocyte maturation. Blood. 1989;74(3):1112–20.PubMedGoogle Scholar
  12. 12.
    Waugh RE. Reticulocyte rigidity and passage through endothelial-like pores. Blood. 1991;78(11):3037–42.PubMedGoogle Scholar
  13. 13.
    Noble NA, Xu QP, Hoge LL. Reticulocytes II: reexamination of the in vivo survival of stress reticulocytes. Blood. 1990;75(9):1877–82.PubMedGoogle Scholar
  14. 14.
    Alfrey CP, Udden MM, Leach-Huntoon C, Driscoll T, Pickett MH. Control of red blood cell mass in spaceflight. J Appl Physiol. 1996;81(1):98–104.PubMedGoogle Scholar
  15. 15.
    Alfrey CP, Rice L, Udden MM, Driscoll TB. Neocytolysis: physiological down-regulator of red-cell mass. Lancet. 1997;349(9062):1389–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Trial J, Rice L, Alfrey CP. Erythropoietin withdrawal alters interactions between young red blood cells, splenic endothelial cells, and macrophages: an in vitro model of neocytolysis. J Investig Med. 2001;49(4):335–45.PubMedCrossRefGoogle Scholar
  17. 17.
    Rice L, Alfrey CP. Modulation of red cell mass by neocytolysis in space and on Earth. Pflugers Arch. 2000;441(2–3 Suppl):R91–4.PubMedGoogle Scholar
  18. 18.
    Rice L, Ruiz W, Driscoll T, et al. Neocytolysis on descent from altitude: a newly recognized mechanism for the control of red cell mass. Ann Intern Med. 2001;134(8):652–6.PubMedGoogle Scholar
  19. 19.
    Risso A, Turello M, Biffoni F, Antonutto G. Red blood cell senescence and neocytolysis in humans after high altitude acclimatization. Blood Cells Mol Dis. 2007;38(2):83–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Trial J, Rice L. Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr Pharm Des. 2004;10(2):183–90.PubMedCrossRefGoogle Scholar
  21. 21.
    Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002;17 Suppl 11:39–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis. 2009;16(2):94–100.PubMedCrossRefGoogle Scholar
  26. 26.
    Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton). 2007;12(4):321–30.CrossRefGoogle Scholar
  27. 27.
    Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif. 2010;29(1):1–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Kwack C, Balakrishnan VS. Managing erythropoietin hyporesponsiveness. Semin Dial. 2006;19(2):146–51.PubMedCrossRefGoogle Scholar
  29. 29.
    Macdougall IC, Cooper AC. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest. 2005;35 Suppl 3:32–5.PubMedCrossRefGoogle Scholar
  30. 30.
    van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol. 2008;4(1):47–57.PubMedCrossRefGoogle Scholar
  31. 31.
    Parfrey PS. Erythropoietin-stimulating agents in chronic kidney disease: a response to hyporesponsiveness. Semin Dial. 2011;24(5):495–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Ait-Oudhia S, Scherrmann JM, Krzyzanski W. Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats. Biopharm Drug Dispos. 2010;31(5–6):298–315.PubMedGoogle Scholar
  33. 33.
    Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther. 1998;64(4):412–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Woo S, Krzyzanski W, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther. 2006;319(3):1297–306.PubMedCrossRefGoogle Scholar
  35. 35.
    Wiczling P, Ait-Oudhia S, Krzyzanski W. Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats. Cytometry A. 2009;75(7):584–92.PubMedGoogle Scholar
  36. 36.
    Donohue DM, Reiff RH, Hanson ML, Betson Y, Finch CA. Quantitative measurement of the erythrocytic and granulocytic cells of the marrow and blood. J Clin Invest. 1958;37(11):1571–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Papayannopoulou T, Finch CA. On the in vivo action of erythropoietin: a quantitative analysis. J Clin Invest. 1972;51(5):1179–85.PubMedCrossRefGoogle Scholar
  38. 38.
    Hermans MH, Opstelten D. In situ visualization of hemopoietic cell subsets and stromal elements in rat and mouse bone marrow by immunostaining of frozen sections. J Histochem Cytochem. 1991;39(12):1627–34.PubMedCrossRefGoogle Scholar
  39. 39.
    Lok CN, Ponka P. Identification of an erythroid active element in the transferrin receptor gene. J Biol Chem. 2000;275(31):24185–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Liu Y, Pop R, Sadegh C, Brugnara C, Haase VH, Socolovsky M. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood. 2006;108(1):123–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Wiczling P, Krzyzanski W. Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model. Cytometry A. 2007;71(7):460–7.PubMedGoogle Scholar
  42. 42.
    Kato M, Kato Y, Sugiyama Y. Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. Am J Physiol. 1999;276(5 Pt 1):E887–95.PubMedGoogle Scholar
  43. 43.
    De Maria R, Testa U, Luchetti L, et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood. 1999;93(3):796–803.PubMedGoogle Scholar
  44. 44.
    Bugelski PJ, Nesspor T, Volk A, et al. Pharmacodynamics of recombinant human erythropoietin in murine bone marrow. Pharm Res. 2008;25(2):369–78.PubMedCrossRefGoogle Scholar
  45. 45.
    Socolovsky M, Murrell M, Liu Y, Pop R, Porpiglia E, Levchenko A. Negative autoregulation by FAS mediates robust fetal erythropoiesis. PLoS Biol. 2007;5(10):e252.PubMedCrossRefGoogle Scholar
  46. 46.
    Singbrant S, Russell MR, Jovic T, et al. Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood. 2011;117(21):5631–42.PubMedCrossRefGoogle Scholar
  47. 47.
    Piron M, Loo M, Gothot A, Tassin F, Fillet G, Beguin Y. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood. 2001;97(2):442–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Locatelli F, Del Vecchio L. Erythropoiesis-stimulating agents in renal medicine. Oncologist. 2011;16 Suppl 3:19–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Xiaoyu Yan
    • 1
  • Sihem Ait-Oudhia
    • 1
  • Wojciech Krzyzanski
    • 1
  1. 1.Department of Pharmaceutical Sciences School of Pharmacy and Pharmaceutical SciencesUniversity at BuffaloBuffaloUSA

Personalised recommendations